• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

New lung cancer treatment launches


The drug, plus chemotherapy, shows a significant survival benefit.

A new drug to treat extensive-stage small cell lung cancer (ES-SCLC) is launching in the U.S.

AstraZeneca recently garnered FDA approval for durvalumab (Imfinzi) as a first-line treatment for adult patients with ES-SCLC in combination with standard-of-care (SoC) chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide).

Related: Lung Cancer Drug Snags Priority Review

SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy. Imfinzi is the only immunotherapy “to show both a significant survival benefit and improved response rate in combination with chemotherapy for these patients, an important step forward in treating this devastating disease,” AstraZeneca says in a press release.

FDA’s approval was based on the Phase 3 CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus SoC alone.

In the IMFINZI plus SoC arm, the risk of death was reduced by 27% with median overall survival of 13 months versus 10.3 months for SoC alone. There was also an increased confirmed objective response rate in the Imfinzi plus SoC arm (68% versus 58% for SoC alone).

Related: Small Molecular Drugs Led 2019 Approvals

“Patients with extensive-stage small cell lung cancer continue to face a poor prognosis, and finding new medicines to improve outcomes in this setting has been a formidable challenge. The CASPIAN trial enables clinicians to choose durvalumab in combination with etoposide and either carboplatin or cisplatin, making this an important new first-line treatment option for patients that is both effective and well-tolerated,” says Jonathan Goldman, MD, associate professor of hematology & oncology at UCLA Medical Center and a lead investigator in the CASPIAN trial.

The most common adverse reactions to Imfinzi were nausea, fatigue/asthenia and alopecia.

Read more: FDA Clears Novel Generic Thyroid Cancer Treatment

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.